Alkermes PLC (NAS:ALKS)
$ 24.34 -0.04 (-0.16%) Market Cap: 4.12 Bil Enterprise Value: 3.75 Bil PE Ratio: 9.62 PB Ratio: 3.28 GF Score: 66/100

Alkermes Plc Investor Event at the 2020 European Society for Medical Oncology Virtual Congress Transcript

Sep 18, 2020 / 12:30PM GMT
Release Date Price: $16.76 (-2.28%)
Operator

Greetings. Welcome to Alkermes ESMO Data Conference Call. My name is Rob and I'll be your operator for today's call. (Operator Instructions) Please note, this conference is being recorded.

I will now turn the call over to Sandra Coombs, Vice President of Investor Relations. Sandy, you may begin.

Sandra Coombs
Alkermes plc - Co-Head of IR

Thank you, and welcome to the Alkermes plc conference call and webcast to discuss new clinical data and updates from our ongoing ARTISTRY-1 clinical trial of ALKS 4230, our investigational agent in oncology. These data are being presented as a mini oral presentation at the European Society for Medical Oncology 2020 Virtual Meeting.

Please note that during today's call, we will reference slides that are available on the webcast. If you have not done so already, please go to the Investors section of our website, alkermes.com, to access the webcast player. A PDF of the slides will be made available on our website following the conclusion of this call.

During this presentation, we will be making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot